Intellia Therapeutics Inc

NTLA

$132.68

+433.3% (1 year change)

Market Cap

$9.68 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$22.17 - $202.73

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

-52.33x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $9.68 Billion
Enterprise Value $9.15 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +433.3%
52-Week High $202.73
52-Week Low $22.17
Beta 2.21
Outstanding Shares 73.5 Million
Avg 30 Day Volume 894 Thousand

Valuation

P/E Ratio -52.33
PEG -46.55
Earnings per Share -$2.90
Price to Sales Ratio Infinity
Price to Book Ratio 22.11
Revenue to Enterprise Value 218.95
EBIT to Enterprise Value -49.23
Total Debt to Enterprise Value 0.0
Debt to Equity 0.0

Profitability

Revenue $41.8 Million
Gross Profit $41.8 Million
EBIT -$186 Million
Net Income -$185 Million
Profit Margin -442.58%
Quarterly Earnings Growth (YoY) +112.4%
Return on Equity -37.4%
Return on Assets -27.53%
Return on Invested Capital -31.08%

Insider trades

No purchases

527,926 shares sold (6 transactions)

No purchases

176,961 shares sold (10 transactions)

No purchases

25,134 shares sold (4 transactions)

No purchases

No sells

Q1 2021 Q2 2021 Q3 2021 Q4 2021

About Intellia Therapeutics Inc

CEO: John Leonard

Employees: 211

Industry: Pharmaceutical Preparation Manufacturing

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.

Similar stocks

Otonomy Inc
ORIC Pharmaceuticals Inc

News

Soundmark Wealth Management, Llc Buys Dimensional U.S. ...

Soundmark Wealth Management, Llc Buys Dimensional U.S. ...

Related Stocks: VOO , VYM , DFAC , DFAX , AVUV , VFVA , AVEM , AVDV , SCHA , SCHF , NTLA , BKI , QQQ ,

GuruFocus GuruFocus, 7 days ago
Harbor Investment Advisory, Llc Buys FIGS Inc, Knowledge Leaders Developed World ETF, The Home ...

Harbor Investment Advisory, Llc Buys FIGS Inc, Knowledge Leaders Developed World ETF, The Home ...

Related Stocks: HD , NTLA , GDX , SLQT , NVDA , IHI , KLDW , FIGS , WKME , QUS , PFIX , JEPI , WORK , WYNN , ZEN , EPC , ACM , VLDR ,

GuruFocus GuruFocus, 8 days ago
Intellia Therapeutics Inc Shares Close the Day 10.4% Lower - Daily Wrap

Intellia Therapeutics Inc Shares Close the Day 10.4% Lower - Daily Wrap

Intellia Therapeutics Inc (NTLA) shares closed today 10.4% lower than it did at the end of yesterday. The stock is currently up 121.9% year-to-date, up 426.2% over the past 12 months, and up 699.4%...

iShook Finance iShook Finance, 10 days ago